News from WCM

Removing race information from cardiovascular risk calculators—which predict the probability of developing heart disease—doesn’t affect patients’ risk scores, according to a study by Weill Cornell Medicine and NewYork-Presbyterian investigators.

A preclinical study by Weill Cornell Medicine investigators shows that a specific human genetic variant of a receptor that stimulates insulin release may help individuals be more resistant to obesity. The researchers discovered that this variant behaves differently in the cell which may contribute to more efficient metabolism.

The eleven students from the Weill Cornell Graduate School of Medical Sciences and the Gerstner Sloan Kettering Graduate School of Biomedical Sciences participated in the eighth annual Three-Minute Thesis (3MT®) competition, which challenged the young scientists to trim the scientific jargon and share their thesis projects creatively.

A historic investment from Board of Fellows member Israel Englander will advance Weill Cornell Medicine’s growing research enterprise and support critical initiatives throughout the institution. 

Researchers at Weill Cornell Medicine have found that controlling high blood pressure may not be enough to prevent associated cognitive declines. The findings point to an immune protein called cytokine IL-17 as a culprit for inducing dementia and suggest new approaches to prevent damage brain cells.

Five people who had life-altering, seemingly irreversible cognitive deficits following moderate to severe traumatic brain injuries showed substantial improvements in their cognition and quality of life after receiving an experimental form of deep brain stimulation (DBS) in a phase 1 clinical trial.

The 11th annual Appel Alzheimer's Disease Research Institute Symposium brought together leading scientists and clinicians in the field to present the latest advances in understanding Alzheimer’s and related neurodegenerative diseases. 

In her new role, Sheil will jointly lead the Office of External Affairs and oversee its more than 40-member Division of Communications and Public Affairs.

Awards, honors and achievements for the month of November.  

The Dean’s Symposium  on Innovation and Entrepreneurship, which took place Nov. 7, celebrated innovation and Weill Cornell Medicine’s entrepreneurial spirit.

Researchers at Weill Cornell Medicine, Cornell Tech and Cornell's Ithaca campus have demonstrated the use of AI-selected natural images and AI-generated synthetic images as neuroscientific tools for probing the visual processing areas of the brain.

Dr. Bishoy M. Faltas, the Gellert Family-John P. Leonard, M.D. Research Scholar and an assistant professor of medicine at Weill Cornell Medicine, has been awarded a $4 million, seven-year MERIT grant from the National Cancer Institute (NCI) at the National Institutes of Health (NIH).

A team led by researchers at Weill Cornell Medicine has used an AI-based approach to uncover underlying patterns among the conditions in which people are born, grow, live, work, and age, termed social determinants of health (SDoH), and then linked each pattern to children’s health outcomes.

Researchers from Weill Cornell Medicine provide the first national estimate of caregivers’ pain and arthritis experiences that can limit their ability to perform necessary tasks while caring for older family members.

Garzio, a distinguished academic medicine administrator, will start her new role in early February.

Researchers at Weill Cornell Medicine found that partnering with local religious leaders boosted adoption of family planning methods in Tanzania.

A team at Weill Cornell Medicine has mapped the location and spatial features of blood-forming cells within human bone marrow.

In patients with severe artery blockage in the lower leg, an artery-supporting device called a resorbable scaffold is superior to angioplasty, which has been the standard treatment, according to the results of a large international clinical trial co-led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.

Researchers at Weill Cornell Medicine have uncovered a novel route to stimulate the growth of healthy insulin-producing pancreatic beta cells in a preclinical model of diabetes. The findings hold promise for future therapeutics that will improve the lives of individuals with type 2 diabetes—a condition that affects more than half a billion people worldwide.

Researchers at Weill Cornell Medicine have demonstrated how amyloid beta, a peptide associated with Alzheimer’s disease, can interact with a protein receptor on immune cells in the brain triggering a reaction that damages blood vessels and leads to neurodegeneration.